Swiss researchers described a wireless subcutaneous implant that removes glucose from circulation by electrocatalytically converting it into gluconate, eliminating the need for drug delivery. In a study in Science, Martin Fussenegger and colleagues at ETH Zurich used mice to test ECHO (electrocatalytic closed-loop health optimization), built from a graphite wafer with gold nanoflake and platinum structures that function as a catalyst. When voltage is applied wirelessly, the implant oxidizes glucose on-device and routes the metabolite through normal processing. The researchers reported that mouse bodies burned roughly a fifth of the resulting gluconate for energy, with the remainder flushed through kidneys, and noted that the implant targeted glucose specifically rather than other circulating sugars. While the work is preclinical and the mechanism behind selectivity was described as not fully explained, the approach signals a different direction for closed-loop metabolic control—based on local chemical processing rather than pharmacokinetic dosing.